Common Equity: The sum of all common equity items.
Salarius Pharmaceuticals, Inc. (SLRX) had Common Equity of $4.25M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-0.87M |
|
-- |
|
-- |
|
$0.90M |
|
$-0.90M |
|
$0.02M |
|
$-0.87M |
|
$-0.87M |
|
$-0.87M |
|
$-0.87M |
|
$-0.87M |
|
$-0.87M |
|
$-0.90M |
|
$-0.89M |
|
0.48M |
|
0.48M |
|
$-1.81 |
|
$-1.81 |
|
| Balance Sheet Financials | |
$6.06M |
|
-- |
|
$0.03M |
|
$6.10M |
|
$1.85M |
|
-- |
|
-- |
|
$1.85M |
|
|
Common Equity |
$4.25M |
$4.25M |
|
$4.25M |
|
0.94M |
|
| Cash Flow Statement Financials | |
$-3.69M |
|
$-0.20M |
|
$6.27M |
|
$2.43M |
|
$4.81M |
|
$2.38M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.56% |
|
-20.56% |
|
-14.33% |
|
-20.56% |
|
$4.50 |
|
$-7.66 |
|
$-7.66 |
|